These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7986740)

  • 21. B cell-activating factor: its clinical significance in multiple myeloma patients.
    Fragioudaki M; Boula A; Tsirakis G; Psarakis F; Spanoudakis M; Papadakis IS; Pappa CA; Alexandrakis MG
    Ann Hematol; 2012 Sep; 91(9):1413-8. PubMed ID: 22526370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum levels of angiopoietin-2 are associated with the growth of multiple myeloma.
    Pappa CA; Tsirakis G; Samiotakis P; Tsigaridaki M; Alegakis A; Goulidaki N; Alexandrakis MG
    Cancer Invest; 2013 Jul; 31(6):385-9. PubMed ID: 23758184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of interleukin-6 in acute pancreatitis. Comparison with C-reactive protein and phospholipase A.
    Viedma JA; Pérez-Mateo M; Domínguez JE; Carballo F
    Gut; 1992 Sep; 33(9):1264-7. PubMed ID: 1427382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
    Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.
    Filella X; Blade J; Guillermo AL; Molina R; Rozman C; Ballesta AM
    Cancer Detect Prev; 1996; 20(1):52-6. PubMed ID: 8907203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors and staging systems of multiple myeloma:
    Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
    Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Classifying ultra-high risk smoldering myeloma.
    Waxman AJ; Mick R; Garfall AL; Cohen A; Vogl DT; Stadtmauer EA; Weiss BM
    Leukemia; 2015 Mar; 29(3):751-3. PubMed ID: 25371175
    [No Abstract]   [Full Text] [Related]  

  • 28. C-reactive protein (CRP) levels do not reflect disease status in patients with multiple myeloma.
    Brown RD; Snowdon L; Uhr E; Gibson J; Joshua D
    Leuk Lymphoma; 1993 Apr; 9(6):509-12. PubMed ID: 8339052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of Bence-Jones proteins, hyperviscosity, hypercalcemia, hyperuricemia and dehydration on development of renal changes in plasma cell dyscrasias.
    Lenert P; Drazen F; Tepavcević P; Pejin D; Curić S; Ilić V; Uzurov V; Popowić S; Zupunski A; Djisalov M
    Przegl Lek; 1985; 42(4):384-6. PubMed ID: 4048525
    [No Abstract]   [Full Text] [Related]  

  • 30. [Clinical value of the blood measurement of the free light chains of immunoglobulins].
    Bidet A; Marit G; Bérard AM
    Ann Biol Clin (Paris); 2008; 66(4):427-31. PubMed ID: 18725344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Serum levels of beta 2-microglobulin in monoclonal gammopathies].
    Pasqualetti P
    Ann Ital Med Int; 1987; 2(1):31-6. PubMed ID: 3152791
    [No Abstract]   [Full Text] [Related]  

  • 32. Daily variations of immunoreactive serum interleukin-6 levels in multiple myeloma.
    Bandieri E; Luppi M; Luppi G; Federico M; Sabbatini R; Torelli G; Piccinini L
    Blood; 1995 Jul; 86(2):832-3. PubMed ID: 7606015
    [No Abstract]   [Full Text] [Related]  

  • 33. Low Protein Z levels in patients with plasma cell neoplasms are inversely correlated with IL-6 levels.
    Gutwein O; Rahimi-Levene N; Herzog-Tzarfati K; Garach-Jehoshua O; Nagler A; Izak M; Koren-Michowitz M
    Leuk Res; 2017 Nov; 62():104-107. PubMed ID: 29031125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
    Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
    Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble IL-6R in plasma cell dyscrasias.
    Smith SR; Morgan L
    Leuk Lymphoma; 1997 Aug; 26(5-6):489-95. PubMed ID: 9389356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients.
    Groblewska M; Mroczko B; Wereszczyńska-Siemiatkowska U; Kedra B; Lukaszewicz M; Baniukiewicz A; Szmitkowski M
    Clin Chem Lab Med; 2008; 46(10):1423-8. PubMed ID: 18844497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impaired production of interleukin 6 and tumour necrosis factor alpha in whole blood cell cultures of patients with multiple myeloma.
    Filella X; Bladé J; Montoto S; Molina R; Coca F; Montserrat E; Ballesta AM
    Cytokine; 1998 Dec; 10(12):993-6. PubMed ID: 10049525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biclonal paraproteinemia: macroglobulinemia-myeloma].
    Rabago Torre L; Velo Bellver JL; Clemente Ricote G; López de la Riva M; Alcalá-Santaella R
    Rev Esp Enferm Apar Dig; 1982 Jul; 62(1):50-5. PubMed ID: 6813927
    [No Abstract]   [Full Text] [Related]  

  • 39. Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index.
    Thaler J; Fechner F; Herold M; Huber H
    Leuk Lymphoma; 1994 Jan; 12(3-4):265-71. PubMed ID: 8167557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone remodelation markers are useful in the management of monoclonal gammopathies.
    Hernández JM; Suquía B; Queizan JA; Fisac RM; Sanchez JJ; Fernández-Calvo FJ; García-Sanz R; Olivier C; Bárez A; Calmuntia MJ; García-Frade J; Portero JA; López R; Aguilera C; Navajo JA; San-Miguel JF
    Hematol J; 2004; 5(6):480-8. PubMed ID: 15570289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.